Alzheimer's disease resident survival guide: Difference between revisions
MoisesRomo (talk | contribs) No edit summary |
No edit summary |
||
(7 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 10px 10px;" cellpadding="0" cellspacing="0"; | |||
|- | |||
! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align=center| {{fontcolor|#2B3B44|Alzheimer's disease Resident Survival Guide Microchapters}} | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Alzheimer's disease resident survival guide#Overview|Overview]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Alzheimer's disease resident survival guide#Causes|Causes]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Alzheimer's disease resident survival guide#Diagnosis|Diagnosis]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Alzheimer's disease resident survival guide#Treatment|Treatment]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Alzheimer's disease resident survival guide#Do's|Do's]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Alzheimer's disease resident survival guide#Don'ts|Don'ts]] | |||
|} | |||
{{WikiDoc CMG}}; {{AE}}{{Fs}} | {{WikiDoc CMG}}; {{AE}}{{Fs}}, [[User:MoisesRomo|Moises Romo M.D.]] | ||
{{SK}}Alzheimer's disease ''management, Alzheimer's disease workup, Alzheimer's disease approach, approach to Alzheimer's disease, Alzheimer's disease treatment'' | {{SK}}Alzheimer's disease ''management, Alzheimer's disease workup, Alzheimer's disease approach, approach to Alzheimer's disease, Alzheimer's disease treatment'' | ||
==Overview== | ==Overview== | ||
'''Alzheimer's disease''' is the most common cause of dementia among older people. Dementia is a loss of thinking, remembering, and reasoning skills that | '''[[Alzheimer's disease]]''' is the most common cause of dementia among older people. [[Dementia]] is a loss of thinking, remembering, and [[reasoning]] skills that interfere with a person's daily life and activities. The [[diagnosis]] of [[Alzheimer's disease|Alzheimer's disease (AD)]] is made on the basis of [[clinical]] criteria described by either the National Institute on Aging and the Alzheimer's Association (NIA-AA) or DSM-V (Diagnostic and Statistical Manual of [[Mental Disorders]], fifth edition). There is no known cure for [[Alzheimer's disease|Alzheimer's disease (AD)]]. Available [[treatments]] offer relatively small [[symptomatic]] benefit but remain [[Palliative care|palliative]] in nature. Current [[treatments]] can be divided into [[pharmacological]], [[psychosocial]], and [[Caregiving and dementia|caregiving]]. | ||
==Causes== | ==Causes== | ||
===Life Threatening Causes=== | ===Life-Threatening Causes=== | ||
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated. | Life-threatening causes include conditions that may result in death or permanent [[disability]] within 24 hours if left untreated. | ||
*Alzheimer's disease is not a life threatening condition that may result in death or permanent disability within 24 hours if left untreated. | *Alzheimer's disease is not a life-threatening condition that may result in death or permanent [[disability]] within 24 hours if left untreated. | ||
===Common Causes=== | ===Common Causes=== | ||
While there is no direct cause for the | While there is no direct cause for the [[development]] of [[Alzheimer's disease]], there are several [[Risk factors|factors]] that may contribute to its acquisition: | ||
*Chromosomal | *[[Chromosomal]] | ||
**'''Down syndrome''' | **'''Down syndrome''' | ||
***Trisomy 21 | ***[[Trisomy 21]] | ||
*** | ***[[Overexpression]] of [[Amyloid precursor protein|amyloid precursor protein (APP)]] on [[chromosome 21]] | ||
***Develop the neuropathologic hallmarks of AD after | ***Develop the neuropathologic hallmarks of [[Alzheimer's disease|AD]] after 40 years of age | ||
*Familial | *[[Familial]] | ||
**'''Late-onset familial (AD2)''' | **'''Late-onset familial (AD2)''' | ||
***APOE gene: | ***[[APOE]] gene: | ||
***TREM2 gene: | ***[[TREM2]] gene: | ||
***PLD3 gene | ***[[PLD3]] gene | ||
***UNC5C gene | ***[[UNC5C]] gene | ||
***AKAP9 gene (in African-Americans only) | ***[[AKAP9]] gene (in African-Americans only) | ||
**'''Early-onset familial AD (AD1, AD3, AD4)''' | **'''Early-onset familial AD (AD1, AD3, AD4)''' | ||
***PSEN1 gene: | ***[[PSEN1]] gene: | ||
***PSEN2 gene: | ***[[PSEN2]] gene: | ||
***APP gene: | ***[[APPI|APP]] gene: | ||
*Unknown (includes genetic/environment interactions) | *Unknown (includes genetic/environment interactions) | ||
**'''Multifactorial''' | **'''Multifactorial''' | ||
***Aging | ***[[Aging]] | ||
***Genetic predisposition | ***[[Genetic]] predisposition | ||
***Exposure to one or more environmental agents including head trauma, low education | ***Exposure to one or more environmental agents including [[head trauma]], low level of education, [[viruses]], and/or [[toxins]] | ||
==Diagnosis== | ==Diagnosis== | ||
Line 49: | Line 65: | ||
or altered level of [[consciousness]]?|B02= Positive for SIGE CAPS questionary?|B03= Yes|B04= [[Depression]]}} | or altered level of [[consciousness]]?|B02= Positive for SIGE CAPS questionary?|B03= Yes|B04= [[Depression]]}} | ||
{{familytree | | | |!| | | | | | | | | |!| | | | }} | {{familytree | | | |!| | | | | | | | | |!| | | | }} | ||
{{familytree | | | B01 | | | | | | | | B02 |-| B03 |-| B04 |-| B05 | | |B01= Yes|B02= No |B03= Severe [[ | {{familytree | | | B01 | | | | | | | | B02 |-| B03 |-| B04 |-| B05 | | |B01= Yes|B02= No |B03= Severe [[impairment]] in [[social functioning]]? |B04= No |B05= [[Normal aging]]}} | ||
{{familytree | | | |!| | | | | | | | | |!| | | | }} | {{familytree | | | |!| | | | | | | | | |!| | | | }} | ||
{{familytree | | | B01 | | | | | | | | B02 | | |B01= [[Delirium]]|B02= [[Dementia]]}} | {{familytree | | | B01 | | | | | | | | B02 | | |B01= [[Delirium]]|B02= [[Dementia]]}} | ||
Line 61: | Line 77: | ||
{{familytree | | |B01| | B02 | | | | |!| | | | B01= No|B02= [[Concussion]], [[post-concussive amnesia]]}} | {{familytree | | |B01| | B02 | | | | |!| | | | B01= No|B02= [[Concussion]], [[post-concussive amnesia]]}} | ||
{{familytree | | | |!| | | | | | | | | |!| | | | }} | {{familytree | | | |!| | | | | | | | | |!| | | | }} | ||
{{familytree | | |B01| | | | | | | | |!| | | | B01= Measure [[urine toxicology]], [[CBC]], [[creatinine]], [[ | {{familytree | | |B01| | | | | | | | |!| | | | B01= Measure [[urine toxicology]], [[CBC]], [[creatinine]], [[electrolytes]], and | ||
[[glucose]] to reveal cause|B02= [[Concussion]], [[post-concussive amnesia]]}} | [[glucose]] to reveal cause|B02= [[Concussion]], [[post-concussive amnesia]]}} | ||
{{familytree | | | | | | | | | | | | | |!| | | | }} | {{familytree | | | | | | | | | | | | | |!| | | | }} | ||
Line 75: | Line 91: | ||
fluctuating [[cognition]], [[visual | fluctuating [[cognition]], [[visual | ||
hallucinations]] | hallucinations]] | ||
| B05= [[Dementia]] | | B05= [[Dementia]] occurring 1 year after onset | ||
of [[Parkinson disease]] | of [[Parkinson disease]] | ||
|| }} | || }} | ||
Line 86: | Line 102: | ||
{{familytree/end}} | {{familytree/end}} | ||
== Treatment == | ==Treatment== | ||
Shown below is an algorithm summarizing the treatment of | Shown below is an [[algorithm]] summarizing the [[treatment]] of [[Alzheimer's disease]] according to the American Academy of Neurology guidelines:<ref name="GrossbergTong2019">{{cite journal|last1=Grossberg|first1=George T.|last2=Tong|first2=Gary|last3=Burke|first3=Anna D.|last4=Tariot|first4=Pierre N.|last5=Fink|first5=Anne|title=Present Algorithms and Future Treatments for Alzheimer’s Disease|journal=Journal of Alzheimer's Disease|volume=67|issue=4|year=2019|pages=1157–1171|issn=13872877|doi=10.3233/JAD-180903}}</ref><br /> | ||
{{ | <br> | ||
{{ | {{Family tree/start}} | ||
{{ | {{Family tree | | | | | | | | | A01 | | | |A01= Patient with diagnosed Alzheimer's disease}} | ||
{{ | {{Family tree | | | | |,|-|-|-|-|^|-|-|-|-|.| | }} | ||
{{ | {{Family tree | | | | C01 | | | | | | | | C02 |C01= Mild to moderate |C02= Moderate to severe }} | ||
{{ | {{Family tree | | | | |!| | | | | | | | | |!| | }} | ||
{{ | {{Family tree | | | | C01 | | | | | | | | |!| |C01= '''Initiate therapy'''<br>•Donepezil. 5 mg once daily; titrate 10 mg once daily<br>•Galantamine (solution). 4 mg twice daily; titrate to 8 mg twice daily<br>•Galantamine (ER capsules). 8 mg once daily; titrate to 16 mg once daily<br>•Rivastigmine (patch). 4.6 mg once daily; titrate to 9.5 mg once daily<br>•Rivastigmine (oral). 1.5 mg twice daily; titrate to 6 mg twice daily }} | ||
{{ | {{Family tree | |,|-|-|^|-|-|.| | | | | | |!| | }} | ||
{{ | {{Family tree | C01 | | | | C02 |-|-|-|-| C03 | | | | | |C01= '''Adverse event'''<br>Consider switch to a different ChEI |C02= '''Disease progression'''<br>Consider high dose or switch to a different ChEI |C03= '''Initiate therapy'''<br>•Donepezil. 5 mg once daily; titrate 10 mg once daily<br>•Rivastigmine (patch). 4.6 mg once daily; titrate to 9.5 mg once daily<br>•Memantine. 5 mg once daily; titrate to 10 mg twice daily or Memantine XR. 7 mg once daily; titrate to 28 mg once daily <br>•Combination ChEI+ Memantine. 7 mg twice daily or 10 mg once daily (ER); titrate to 10 mg twice daily or 28 mg once daily (ER) }} | ||
{{ | {{Family tree | | | | | | | | | | | | | | |!| | }} | ||
{{ | {{Family tree | | | | | | | | | | | | | | C01 |C01= '''Monitor and reevaluate therapy'''<br>Monitor every 3-4 months and titrate dose as needed }} | ||
{{ | {{Family tree | | | | | | | | | | | |,|-|-|^|-|-|.| | }} | ||
{{ | {{Family tree | | | | | | | | | | | C01 | | | | C02 |C01= '''Adverse event'''<br>Consider switch to a different therapy |C02= '''Disease progression'''<br>Consider higher dose or switch to a different therapy }} | ||
{{Family tree | | | | | | | | | | | | | | | | | |!| | }} | |||
{{Family tree | | | | | | | | | | | | | | | | | C01 |C01= '''Discontinue therapy'''<br>When all cognitive function and functional abilities are lost at terminal stages of AD}} | |||
{{Family tree/end}} | |||
<br> | |||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
Line 111: | Line 131: | ||
*Engage in regular [https://www.wikidoc.org/index.php/Physical_activity physical activity]. | *Engage in regular [https://www.wikidoc.org/index.php/Physical_activity physical activity]. | ||
*Maintain leisure and social activities – keep socially engaged. | *Maintain leisure and social activities – keep socially engaged. | ||
*Continue or | *Continue or start activities that help to stimulate the [https://www.wikidoc.org/index.php/Brain brain], e.g., Tai Chi, dancing, puzzles. | ||
*Become educated about [https://www.wikidoc.org/index.php/Dementia dementia] and seek support from others with dementia, e.g., the [https://www.wikidoc.org/index.php/Alzheimer's_Association Alzheimer's Association], Keep Memory Alive, and other community groups. | *Become educated about [https://www.wikidoc.org/index.php/Dementia dementia] and seek support from others with dementia, e.g., the [https://www.wikidoc.org/index.php/Alzheimer's_Association Alzheimer's Association], Keep Memory Alive, and other community groups. | ||
*Include music in daily life – listening to music, playing an instrument, singing. | *Include music in daily life – listening to music, playing an instrument, singing. | ||
Line 119: | Line 139: | ||
|<blockquote>Do not modify</blockquote> | |<blockquote>Do not modify</blockquote> | ||
|} | |} | ||
== | ==Dos== | ||
*Perform [https://www.wikidoc.org/index.php/Laboratory laboratory testing] to exclude potentially reversible causes of [https://www.wikidoc.org/index.php/Amnesia amnesia]. Initial tests should include a [https://www.wikidoc.org/index.php/CBC CBC], [https://www.wikidoc.org/index.php/Toxicology_screen urine toxicology], [https://www.wikidoc.org/index.php/Thyroid_function_tests thyroid function], [https://www.wikidoc.org/index.php/Folate_deficiency folate], and [https://www.wikidoc.org/index.php/Vitamin_B12 vitamin B12] level. | *Perform [https://www.wikidoc.org/index.php/Laboratory laboratory testing] to exclude potentially reversible causes of [https://www.wikidoc.org/index.php/Amnesia amnesia]. Initial tests should include a [https://www.wikidoc.org/index.php/CBC CBC], [https://www.wikidoc.org/index.php/Toxicology_screen urine toxicology], [https://www.wikidoc.org/index.php/Thyroid_function_tests thyroid function], [https://www.wikidoc.org/index.php/Folate_deficiency folate], and [https://www.wikidoc.org/index.php/Vitamin_B12 vitamin B12] level. | ||
*When | *When performing [[cognitive]] assessment, use tests such as [https://www.wikidoc.org/index.php/MMSE MMSE], Mini-cog, [https://www.wikidoc.org/index.php/MoCA MoCA], SIB-8, and AD8.<ref name="pmid1202204">{{cite journal |vauthors=Folstein MF, Folstein SE, McHugh PR |title="Mini-mental state". A practical method for grading the cognitive state of patients for the clinician |journal=J Psychiatr Res |volume=12 |issue=3 |pages=189–98 |date=November 1975 |pmid=1202204 |doi=10.1016/0022-3956(75)90026-6 |url=}}</ref><ref name="pmid14511167">{{cite journal |vauthors=Borson S, Scanlan JM, Chen P, Ganguli M |title=The Mini-Cog as a screen for dementia: validation in a population-based sample |journal=J Am Geriatr Soc |volume=51 |issue=10 |pages=1451–4 |date=October 2003 |pmid=14511167 |doi=10.1046/j.1532-5415.2003.51465.x |url=}}</ref><ref name="pmid15817019">{{cite journal |vauthors=Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H |title=The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment |journal=J Am Geriatr Soc |volume=53 |issue=4 |pages=695–9 |date=April 2005 |pmid=15817019 |doi=10.1111/j.1532-5415.2005.53221.x |url=}}</ref><ref name="pmid19571727">{{cite journal |vauthors=Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H |title=A brief instrument to assess treatment response in the patient with advanced Alzheimer disease |journal=Alzheimer Dis Assoc Disord |volume=23 |issue=4 |pages=377–83 |date=2009 |pmid=19571727 |doi=10.1097/WAD.0b013e3181ac9cc1 |url=}}</ref> | ||
*When determining level of independence and level of disability, use test such as ADCS–ADL.<ref name="pmid195717272">{{cite journal |vauthors=Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H |title=A brief instrument to assess treatment response in the patient with advanced Alzheimer disease |journal=Alzheimer Dis Assoc Disord |volume=23 |issue=4 |pages=377–83 |date=2009 |pmid=19571727 |doi=10.1097/WAD.0b013e3181ac9cc1 |url=}}</ref> | *When determining level of independence and level of [[disability]], use test such as ADCS–ADL.<ref name="pmid195717272">{{cite journal |vauthors=Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H |title=A brief instrument to assess treatment response in the patient with advanced Alzheimer disease |journal=Alzheimer Dis Assoc Disord |volume=23 |issue=4 |pages=377–83 |date=2009 |pmid=19571727 |doi=10.1097/WAD.0b013e3181ac9cc1 |url=}}</ref> | ||
*When determining the level of [https://www.wikidoc.org/index.php/Behavioral behavioral] [https://www.wikidoc.org/index.php/Symptoms symptoms], use the NPI-Q test.<ref name="pmid11001602">{{cite journal |vauthors=Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST |title=Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory |journal=J Neuropsychiatry Clin Neurosci |volume=12 |issue=2 |pages=233–9 |date=2000 |pmid=11001602 |doi=10.1176/jnp.12.2.233 |url=}}</ref> | *When determining the level of [https://www.wikidoc.org/index.php/Behavioral behavioral] [https://www.wikidoc.org/index.php/Symptoms symptoms], use the NPI-Q test.<ref name="pmid11001602">{{cite journal |vauthors=Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST |title=Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory |journal=J Neuropsychiatry Clin Neurosci |volume=12 |issue=2 |pages=233–9 |date=2000 |pmid=11001602 |doi=10.1176/jnp.12.2.233 |url=}}</ref> | ||
*Identify primary caregiver and assess | *Identify primary caregiver and assess their health, as well as adequacy of family and other support systems.<ref name="pmid25815358">{{cite journal |vauthors=Cummings JL, Isaacson RS, Schmitt FA, Velting DM |title=A practical algorithm for managing Alzheimer's disease: what, when, and why? |journal=Ann Clin Transl Neurol |volume=2 |issue=3 |pages=307–23 |date=March 2015 |pmid=25815358 |doi=10.1002/acn3.166 |url=}}</ref> | ||
*[https://www.wikidoc.org/index.php/Neuroimaging Neuroimaging] may diagnose [https://www.wikidoc.org/index.php/Vascular_disease vascular disease], [https://www.wikidoc.org/index.php/Normal_pressure_hydrocephalus normal pressure hydrocephalus], [https://www.wikidoc.org/index.php/Tumors tumors], [https://www.wikidoc.org/index.php/Abscess abscess].<ref name="pmid11342678">{{cite journal |vauthors=Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC |title=Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology |journal=Neurology |volume=56 |issue=9 |pages=1143–53 |date=May 2001 |pmid=11342678 |doi=10.1212/wnl.56.9.1143 |url=}}</ref> | *[https://www.wikidoc.org/index.php/Neuroimaging Neuroimaging] may diagnose [https://www.wikidoc.org/index.php/Vascular_disease vascular disease], [https://www.wikidoc.org/index.php/Normal_pressure_hydrocephalus normal pressure hydrocephalus], [https://www.wikidoc.org/index.php/Tumors tumors], [https://www.wikidoc.org/index.php/Abscess abscess].<ref name="pmid11342678">{{cite journal |vauthors=Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC |title=Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology |journal=Neurology |volume=56 |issue=9 |pages=1143–53 |date=May 2001 |pmid=11342678 |doi=10.1212/wnl.56.9.1143 |url=}}</ref> | ||
*Perform a minimental status test on [https://www.wikidoc.org/index.php/Physical_examination physical examination] and pay | *Perform a minimental status test on [https://www.wikidoc.org/index.php/Physical_examination physical examination] and pay special attention to [https://www.wikidoc.org/index.php/Concentration concentration] domain. Minimental testing has the potential to distinguish mild [https://www.wikidoc.org/index.php/Cognitive_impairment cognitive impairment] from [https://www.wikidoc.org/index.php/Dementia dementia].<ref name="pmid113426772">{{cite journal |vauthors=Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST |title=Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology |journal=Neurology |volume=56 |issue=9 |pages=1133–42 |date=May 2001 |pmid=11342677 |doi=10.1212/wnl.56.9.1133 |url=}}</ref> | ||
*Always have in mind [https://www.wikidoc.org/index.php/Depression depression] as a possible cause of [https://www.wikidoc.org/index.php/Amnesia memory | *Always have in mind [https://www.wikidoc.org/index.php/Depression depression] as a possible cause of [https://www.wikidoc.org/index.php/Amnesia memory impairment]. [https://www.wikidoc.org/index.php/Depression Depression] is common cause of [https://www.wikidoc.org/index.php/Amnesia amnesia]; a SIGE CAPS evaluation may disclose an underlying [https://www.wikidoc.org/index.php/Mood_disorder mood disorder].<ref name="pmid323564722">{{cite journal |vauthors=Squire LR, Zouzounis JA |title=Self-ratings of memory dysfunction: different findings in depression and amnesia |journal=J Clin Exp Neuropsychol |volume=10 |issue=6 |pages=727–38 |date=December 1988 |pmid=3235647 |doi=10.1080/01688638808402810 |url=}}</ref>. | ||
==Don'ts== | ==Don'ts== | ||
Line 136: | Line 156: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Resident survival guide]] | [[Category:Resident survival guide]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
Latest revision as of 18:54, 19 February 2021
Alzheimer's disease Resident Survival Guide Microchapters |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Moises Romo M.D.
Synonyms and keywords:Alzheimer's disease management, Alzheimer's disease workup, Alzheimer's disease approach, approach to Alzheimer's disease, Alzheimer's disease treatment
Overview
Alzheimer's disease is the most common cause of dementia among older people. Dementia is a loss of thinking, remembering, and reasoning skills that interfere with a person's daily life and activities. The diagnosis of Alzheimer's disease (AD) is made on the basis of clinical criteria described by either the National Institute on Aging and the Alzheimer's Association (NIA-AA) or DSM-V (Diagnostic and Statistical Manual of Mental Disorders, fifth edition). There is no known cure for Alzheimer's disease (AD). Available treatments offer relatively small symptomatic benefit but remain palliative in nature. Current treatments can be divided into pharmacological, psychosocial, and caregiving.
Causes
Life-Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Alzheimer's disease is not a life-threatening condition that may result in death or permanent disability within 24 hours if left untreated.
Common Causes
While there is no direct cause for the development of Alzheimer's disease, there are several factors that may contribute to its acquisition:
- Chromosomal
- Down syndrome
- Trisomy 21
- Overexpression of amyloid precursor protein (APP) on chromosome 21
- Develop the neuropathologic hallmarks of AD after 40 years of age
- Down syndrome
- Familial
- Unknown (includes genetic/environment interactions)
- Multifactorial
- Aging
- Genetic predisposition
- Exposure to one or more environmental agents including head trauma, low level of education, viruses, and/or toxins
- Multifactorial
Diagnosis
Shown below is an algorithm summarizing the diagnosis of amnesia according to the the American Academy of Neurology guidelines:[1]
Treatment
Shown below is an algorithm summarizing the treatment of Alzheimer's disease according to the American Academy of Neurology guidelines:[2]
Patient with diagnosed Alzheimer's disease | |||||||||||||||||||||||||||||||||||||||||
Mild to moderate | Moderate to severe | ||||||||||||||||||||||||||||||||||||||||
Initiate therapy •Donepezil. 5 mg once daily; titrate 10 mg once daily •Galantamine (solution). 4 mg twice daily; titrate to 8 mg twice daily •Galantamine (ER capsules). 8 mg once daily; titrate to 16 mg once daily •Rivastigmine (patch). 4.6 mg once daily; titrate to 9.5 mg once daily •Rivastigmine (oral). 1.5 mg twice daily; titrate to 6 mg twice daily | |||||||||||||||||||||||||||||||||||||||||
Adverse event Consider switch to a different ChEI | Disease progression Consider high dose or switch to a different ChEI | Initiate therapy •Donepezil. 5 mg once daily; titrate 10 mg once daily •Rivastigmine (patch). 4.6 mg once daily; titrate to 9.5 mg once daily •Memantine. 5 mg once daily; titrate to 10 mg twice daily or Memantine XR. 7 mg once daily; titrate to 28 mg once daily •Combination ChEI+ Memantine. 7 mg twice daily or 10 mg once daily (ER); titrate to 10 mg twice daily or 28 mg once daily (ER) | |||||||||||||||||||||||||||||||||||||||
Monitor and reevaluate therapy Monitor every 3-4 months and titrate dose as needed | |||||||||||||||||||||||||||||||||||||||||
Adverse event Consider switch to a different therapy | Disease progression Consider higher dose or switch to a different therapy | ||||||||||||||||||||||||||||||||||||||||
Discontinue therapy When all cognitive function and functional abilities are lost at terminal stages of AD | |||||||||||||||||||||||||||||||||||||||||
Recommendations for maintaining brain health in elderly patients with and without Alzheimer's Disease |
---|
|
|
Dos
- Perform laboratory testing to exclude potentially reversible causes of amnesia. Initial tests should include a CBC, urine toxicology, thyroid function, folate, and vitamin B12 level.
- When performing cognitive assessment, use tests such as MMSE, Mini-cog, MoCA, SIB-8, and AD8.[3][4][5][6]
- When determining level of independence and level of disability, use test such as ADCS–ADL.[7]
- When determining the level of behavioral symptoms, use the NPI-Q test.[8]
- Identify primary caregiver and assess their health, as well as adequacy of family and other support systems.[9]
- Neuroimaging may diagnose vascular disease, normal pressure hydrocephalus, tumors, abscess.[10]
- Perform a minimental status test on physical examination and pay special attention to concentration domain. Minimental testing has the potential to distinguish mild cognitive impairment from dementia.[11]
- Always have in mind depression as a possible cause of memory impairment. Depression is common cause of amnesia; a SIGE CAPS evaluation may disclose an underlying mood disorder.[12].
Don'ts
- If alcoholism and thiamine deficiency is suspected, do not administer glucose before thiamine. Administration of glucose before thiamine may lead to Wernicke encephalopathy.[13]
References
- ↑ Jahn H (December 2013). "Memory loss in Alzheimer's disease". Dialogues Clin Neurosci. 15 (4): 445–54. PMC 3898682. PMID 24459411.
- ↑ Grossberg, George T.; Tong, Gary; Burke, Anna D.; Tariot, Pierre N.; Fink, Anne (2019). "Present Algorithms and Future Treatments for Alzheimer's Disease". Journal of Alzheimer's Disease. 67 (4): 1157–1171. doi:10.3233/JAD-180903. ISSN 1387-2877.
- ↑ Folstein MF, Folstein SE, McHugh PR (November 1975). ""Mini-mental state". A practical method for grading the cognitive state of patients for the clinician". J Psychiatr Res. 12 (3): 189–98. doi:10.1016/0022-3956(75)90026-6. PMID 1202204.
- ↑ Borson S, Scanlan JM, Chen P, Ganguli M (October 2003). "The Mini-Cog as a screen for dementia: validation in a population-based sample". J Am Geriatr Soc. 51 (10): 1451–4. doi:10.1046/j.1532-5415.2003.51465.x. PMID 14511167.
- ↑ Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (April 2005). "The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment". J Am Geriatr Soc. 53 (4): 695–9. doi:10.1111/j.1532-5415.2005.53221.x. PMID 15817019.
- ↑ Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H (2009). "A brief instrument to assess treatment response in the patient with advanced Alzheimer disease". Alzheimer Dis Assoc Disord. 23 (4): 377–83. doi:10.1097/WAD.0b013e3181ac9cc1. PMID 19571727.
- ↑ Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H (2009). "A brief instrument to assess treatment response in the patient with advanced Alzheimer disease". Alzheimer Dis Assoc Disord. 23 (4): 377–83. doi:10.1097/WAD.0b013e3181ac9cc1. PMID 19571727.
- ↑ Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000). "Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory". J Neuropsychiatry Clin Neurosci. 12 (2): 233–9. doi:10.1176/jnp.12.2.233. PMID 11001602.
- ↑ Cummings JL, Isaacson RS, Schmitt FA, Velting DM (March 2015). "A practical algorithm for managing Alzheimer's disease: what, when, and why?". Ann Clin Transl Neurol. 2 (3): 307–23. doi:10.1002/acn3.166. PMID 25815358.
- ↑ Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (May 2001). "Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 56 (9): 1143–53. doi:10.1212/wnl.56.9.1143. PMID 11342678.
- ↑ Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (May 2001). "Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 56 (9): 1133–42. doi:10.1212/wnl.56.9.1133. PMID 11342677.
- ↑ Squire LR, Zouzounis JA (December 1988). "Self-ratings of memory dysfunction: different findings in depression and amnesia". J Clin Exp Neuropsychol. 10 (6): 727–38. doi:10.1080/01688638808402810. PMID 3235647.
- ↑ Hack, Jason B.; Hoffman, Robert S. (1998). "Thiamine Before Glucose to Prevent Wernicke Encephalopathy: Examining the Conventional Wisdom". JAMA. 279 (8): 583. doi:10.1001/jama.279.8.583a. ISSN 0098-7484.